<i id='08A114197B'><strike id='08A114197B'><tt id='08A114197B'><pre id='08A114197B'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
George Santos makes 1st court appearance after pleading not guilty to 13 counts 
Men with early prostate cancer can safely opt out of treatment 
Heart attack and stroke risk calculators need revising 
With fresh data, a dynamic duo powers Eli Lilly to new heights 
Continuity nursing helped my family in our darkest PICU moments 
How to protect coverage of PrEP 
Walensky prepares to leave CDC — and Congress — behind 
Drinking water from half of US faucets contains PFAS: Study 
New air purifier tech could be key to improving indoor air quality 
Rare Northern Lights show in US this week: Where and how to see it
New air purifier tech could be key to improving indoor air quality 
Malaysia cuts short music fest after British band slams anti 
Peter Hotez and the public health issue of online harassment 
North Korean leader's powerful sister says warplanes repelled US spy plane 
In Memoriam: Notable people who died in 2023 
